Literature DB >> 16616351

Natural history of intraductal papillary mucinous tumors of the pancreas: actuarial risk of malignancy.

Philippe Lévy1, Vincent Jouannaud, Dermot O'Toole, Anne Couvelard, Marie Pierre Vullierme, Laurent Palazzo, Alain Aubert, Philippe Ponsot, Alain Sauvanet, Frédérique Maire, Olivia Hentic, Pascal Hammel, Philippe Ruszniewski.   

Abstract

BACKGROUND & AIMS: Natural history of intraductal papillary mucinous tumors of the pancreas (IPMTs) is unknown. Cross-sectional studies suggest that exclusive branch duct (BD) involvement is associated with a lower risk of carcinoma than main pancreatic duct (MPD) involvement. The aim of our study was to calculate longitudinal risk of malignant transformation of IPMT since the first sign.
METHODS: All the patients with a diagnosis of highly probable or histologically proven IPMT were included. Actuarial risks of occurrence of at least low-grade dysplasia (>or=LGD), high-grade dysplasia (>or=HGD), or invasive carcinoma (IC) were calculated by Kaplan-Meier method from the first sign attributable to IPMT. The risks according to sex, acute pancreatitis, tumor size, and involvement of MPD were compared by log-rank test.
RESULTS: One hundred six patients were included with a proven (n = 76) or probable (n = 30) IPMT. The tumor was confined to BD in 53 cases. Median duration since the onset of the first sign to the end of follow-up was 21 months (range, 0-241). Ten-year actuarial risk that IPMT grade was >or=LGD, >or=HGD, or IC was 67%, 49%, and 29%, respectively. The only morphologic risk factor of malignant transformation was involvement of MPD, with a 5-year actuarial risk of >or=HGD of 63% in the MPD group compared with 15% in the BD group (P < .001).
CONCLUSIONS: Longitudinal risk of at least HGD or IC is time-dependent. Patients with BD IPMT present a much lower risk, justifying a nonoperative surveillance.

Entities:  

Mesh:

Year:  2006        PMID: 16616351     DOI: 10.1016/j.cgh.2006.01.018

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  66 in total

1.  Simultaneous intraductal papillary neoplasms of the bile duct and pancreas treated with chemoradiotherapy.

Authors:  Roberto Valente; Gabriele Capurso; Paola Pierantognetti; Elsa Iannicelli; Matteo Piciucchi; Adriana Romiti; Paolo Mercantini; Alberto Larghi; Giulia Francesca Federici; Viola Barucca; Maria Falchetto Osti; Emilio Di Giulio; Vincenzo Ziparo; Gianfranco Delle Fave
Journal:  World J Gastrointest Oncol       Date:  2012-02-15

2.  Clinicopathologic analysis of surgically proven intraductal papillary mucinous neoplasms of the pancreas in SNUH: a 15-year experience at a single academic institution.

Authors:  Dae Wook Hwang; Jin-Young Jang; Seung Eun Lee; Chang-Sup Lim; Kuhn Uk Lee; Sun-Whe Kim
Journal:  Langenbecks Arch Surg       Date:  2010-07-18       Impact factor: 3.445

Review 3.  Intraductal papillary mucinous neoplasms of the pancreas: making a disposition using the natural history.

Authors:  L William Traverso; Toshiyuki Moriya; Yasushi Hashimoto
Journal:  Curr Gastroenterol Rep       Date:  2012-04

Review 4.  Biology and management of pancreatic cancer.

Authors:  Paula Ghaneh; Eithne Costello; John P Neoptolemos
Journal:  Gut       Date:  2007-08       Impact factor: 23.059

Review 5.  [Importance of endoscopy and endosonography for chronic pancreatitis and benign pancreas tumors].

Authors:  M Fuchs; W Schepp
Journal:  Radiologe       Date:  2008-08       Impact factor: 0.635

6.  Natural History of Patients Followed Radiographically with Mucinous Cysts of the Pancreas.

Authors:  Linda M Pak; Michael I D'Angelica; Ronald P DeMatteo; T Peter Kingham; Vinod P Balachandran; William R Jarnagin; Peter J Allen
Journal:  J Gastrointest Surg       Date:  2017-05-17       Impact factor: 3.452

7.  Mucinous nonneoplastic cyst of the pancreas: apomucin phenotype distinguishes this entity from intraductal papillary mucinous neoplasm.

Authors:  Wenqing Cao; Brain P Adley; Jie Liao; Xiaoqi Lin; Mark Talamonti; David J Bentrem; Sambasiva M Rao; Guang-Yu Yang
Journal:  Hum Pathol       Date:  2009-12-01       Impact factor: 3.466

8.  Pancreatic and extrapancreatic lesions in patients with intraductal papillary mucinous neoplasms of the pancreas: a single-centre experience.

Authors:  L Calculli; R Pezzilli; C Brindisi; R Morabito; R Casadei; M Zompatori
Journal:  Radiol Med       Date:  2010-01-15       Impact factor: 3.469

9.  Consensus guidelines in the management of branch duct intraductal papillary mucinous neoplasm: a cost-effectiveness analysis.

Authors:  Edward S Huang; G Scott Gazelle; Chin Hur
Journal:  Dig Dis Sci       Date:  2009-10-16       Impact factor: 3.199

10.  Mucin-producing neoplasms of the pancreas: an analysis of distinguishing clinical and epidemiologic characteristics.

Authors:  Stefano Crippa; Carlos Fernández-Del Castillo; Roberto Salvia; Dianne Finkelstein; Claudio Bassi; Ismael Domínguez; Alona Muzikansky; Sarah P Thayer; Massimo Falconi; Mari Mino-Kenudson; Paola Capelli; Gregory Y Lauwers; Stefano Partelli; Paolo Pederzoli; Andrew L Warshaw
Journal:  Clin Gastroenterol Hepatol       Date:  2009-10-14       Impact factor: 11.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.